Search Results for:  – Page 7

In case you missed it, WTOP’s Mitchell Miller spoke with former U.S. Senator Pat Toomey (R-PA) about the current health care debate in Congress in a conversation titled; “The Political And Economic Ramifications Of Undermining The Free Market In Health

In case you missed it, Jason Altmire, former Democratic three-term U.S. Representative from Pennsylvania and current adjunct professor at Texas Tech University, explains why so-called “delinking” proposals would be catastrophic for patients and families’ pocketbooks in an op-ed in RealClearHealth.

So-called “delinking” policies continue to be discussed in Congress. Among several glaring problems — including a rejection of free market performance-based incentives that lower drug costs for consumers — if enacted, “delinking” would hand a financial windfall totaling up to

Millions of Patients Impacted if Option to Use Spread Pricing is Taken Away Pharmacy benefit companies offer employers and health plans flexibility when they’re designing their pharmacy benefits. From formularies to compensation, there are choices for employers and plans to

A team of professors from Johns Hopkins University, Georgetown Law School, and Utah University College of Pharmacy published in the JAMA Health Forum a paper, “Pharmacy Benefit Managers: History, Business Practices, Economics, and Policy,” focused on pharmacy benefit companies and

As Congress considers anti-PBM legislation in the new year, it is important lawmakers are aware that allowing the government to dictate the winners and losers in the health care system, according to policymakers and experts, will do nothing to actually

In case you missed it, a new PCMA Rx Research Corner blog highlighted the value employers find in their pharmacy benefit company relationships. As Congress considers passing misguided proposals in the new year that will undermine the critical flexibility and